Inhalation Sciences AB (ISAB) has received an order worth SEK 1.9 million (EUR 178,000) for an Inhalation Research Service (IRS) project with a mid-sized US pharma company. The project will use ISAB's leading in vitrodissolution and absorption module DissolvIt to test the dissolution profiles of a new inhaled drug. The project will test the dissolution profiles of a new drug with several formulations, both with and without excipients.

It will also test if the drug's dissolution properties are maintained when scaling up production. ISAB's in vitro dissolution technology - DissolvIt - can discriminate and generate comprehensive data across several testing micronization methods, formulations and APIs.